



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: BTZ043

产品别名: BTZ043

生物活性:

Description	BTZ043 is an inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), with MICs of 2.3 nM and 9.2 nM for M. tuberculosis H37Rv and Mycobacterium smegmatis, respectively.																							
IC₅₀ & Target	DprE1[1].																							
In Vitro	The MIC of BTZ043 against M. tuberculosis H37Rv and Mycobacterium smegmatis are 1 ng/mL (2.3 nM) and 4 ng/mL (9.2 nM), respectively[2]. The in vitro activity of BTZ043 against 30 Nocardia brasiliensis isolates is also tested. The MIC ₅₀ and MIC ₉₀ values for BTZ043 are 0.125 and 0.25 µg/mL. The MIC for N. carnea ATCC 6847 is 0.003µg/mL, for N. transvalensis ATCC 6865 is 0.003µg/mL, for N. brasiliensis NCTC10300 is 0.03 µg/mL, and for N. brasiliensis HUJEG-1 is 0.125µg/mL. The MIC value for M. tuberculosis H37Rv is 0.000976 µg/mL. The MIC value of BTZ-043 is >64 µg/mL for Escherichia coli ATCC 25922 and S. aureus ATCC 29213[3].																							
In Vivo	Four weeks of treatment with BTZ043 reduces the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively, at the concentrations used. Additional results suggest that BTZ043 efficacy is time-rather than dose-dependent. Acute (5 g/kg) and chronic (25 and 250 mg/kg) toxicology studies in uninfected mice show that, even at the highest dose tested, there are no adverse anatomical, behavioral, or physiological effects after one month[2].																							
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : 13.3 mg/mL (30.83 mM; Need ultrasonic and warming)</p> <p>H₂O : < 0.1 mg/mL (insoluble)</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent</th><th>Mass</th><th rowspan="2">1 mg</th><th rowspan="2">5 mg</th><th rowspan="2">10 mg</th></tr><tr><th>Concentration</th></tr></thead><tbody><tr><td>1 mM</td><td>2.3181 mL</td><td>11.5904 mL</td><td>23.1809 mL</td></tr><tr><td>5 mM</td><td>0.4636 mL</td><td>2.3181 mL</td><td>4.6362 mL</td></tr><tr><td>10 mM</td><td>0.2318 mL</td><td>1.1590 mL</td><td>2.3181 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用, -20°C 储存时,请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:</p> <p>——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: 2.5 mg/mL (5.80 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2.5 mg/mL (5.80 mM)的均匀悬浊液,悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例,取 100 µL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 µL PEG300 中,混合均匀。</p>					Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg	Concentration	1 mM	2.3181 mL	11.5904 mL	23.1809 mL	5 mM	0.4636 mL	2.3181 mL	4.6362 mL	10 mM	0.2318 mL	1.1590 mL	2.3181 mL
Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg																			
	Concentration																							
1 mM	2.3181 mL	11.5904 mL	23.1809 mL																					
5 mM	0.4636 mL	2.3181 mL	4.6362 mL																					
10 mM	0.2318 mL	1.1590 mL	2.3181 mL																					



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

	<p>向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂: 10% DMSO → 90% (20% SBE-β-CD in saline)</p> <p>Solubility: 2.5 mg/mL (5.80 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2.5 mg/mL (5.80 mM) 的均匀悬浊液, 悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水溶液中, 混合均匀。</p> <p>3. 请依序添加每种溶剂: 10% DMSO → 90% corn oil</p> <p>Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (5.80 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。</p>
References	<p>[1]. Vadim Makarov et al. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 fromMycobacterium tuberculosis. <i>Antimicrob Agents Chemother</i>, 2015 Aug, 59(8): 4446-4452.</p> <p>[2]. Makarov V, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. <i>Science</i>. 2009 May 8;324(5928):801-4.</p> <p>[3]. Norma Alejandra González-Martínez et al. In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis. <i>PLoS Negl Trop Dis</i>, 2015 Oct, 9(10): e0004022.</p>
实验参考:	
Animal Administration	<p>Mice[2]</p> <p>Animal efficacy is determined in a standard mouse infection model. BALB/c mice are infected with a low bacillary load (~200 CFU) of <i>M. tuberculosis</i> H37Rv via aerosol. Treatment started four-weeks post infection. Mice are dosed by gavage with 37.5, or 300 mg of BTZ043, per kg body weight, in carboxymethyl cellulose formulation (0.25%), once daily, six times/week, for four weeks. Control and treated mice are sacrificed, lungs and spleens homogenized and dilutions plated for enumeration of viable bacilli[2].</p>
References	<p>[1]. Vadim Makarov et al. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 fromMycobacterium tuberculosis. <i>Antimicrob Agents Chemother</i>, 2015 Aug, 59(8): 4446-4452.</p> <p>[2]. Makarov V, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. <i>Science</i>. 2009 May 8;324(5928):801-4.</p> <p>[3]. Norma Alejandra González-Martínez et al. In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis. <i>PLoS Negl Trop Dis</i>, 2015 Oct, 9(10): e0004022.</p>